Role of GLP1-RA in Optimizing Weight Loss Post-Bariatric Surgery: A Systematic Review and Meta-Analysis.
Mable PereiraShenelle MenezesAncy Jenil FrancoPatricia MarcolinMark TomeraPublished in: Obesity surgery (2024)
Bariatric surgery is a widely used intervention for significant weight loss, yet some patients face challenges with insufficient weight loss or weight regain post-surgery. To address this issue, adjunctive treatments like glucagon-like peptide-1 receptor agonists (GLP1-RAs) are being explored for their potential to enhance weight loss outcomes. This meta-analysis was conducted to evaluate the effectiveness of GLP1-RAs in improving weight loss after bariatric surgery compared to a placebo. By systematically reviewing and analyzing data from three randomized controlled trials (RCTs) involving 130 patients, we found that GLP1-RA therapy, particularly liraglutide (1.8-3 mg), significantly reduced mean BMI and body weight percentage at six months. Future studies should explore newer GLP1-RAs with weekly dosing and include longer follow-up periods to assess the durability of these outcomes.
Keyphrases
- weight loss
- bariatric surgery
- gastric bypass
- roux en y gastric bypass
- obese patients
- randomized controlled trial
- end stage renal disease
- systematic review
- body weight
- ejection fraction
- chronic kidney disease
- glycemic control
- newly diagnosed
- weight gain
- rheumatoid arthritis
- body mass index
- minimally invasive
- type diabetes
- meta analyses
- ankylosing spondylitis
- disease activity
- skeletal muscle
- mesenchymal stem cells
- systemic sclerosis
- wild type
- deep learning
- systemic lupus erythematosus
- human health
- open label
- big data
- patient reported